Thermo Fisher Scientific, Inc. (TMO) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (reve...
Thermo Fisher Scientific, Inc.'s revenue increased 3.9% year over year, from $42.88B to $44.56B.
Net income increased 5.8% over the same period, from $6.33B to $6.70B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 144% in total.
Total debt increased by 25.9% to $39.38B.
The debt-to-equity ratio stands at 0.74, indicating a moderate leverage profile.
Operating cash flow declined 9.8% to $7.82B.
Thermo Fisher Scientific, Inc. maintains a healthy net profit margin of 15.0%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $31.97B+49.4% | $4.37B | $12.71B | $5.00B | $4.68B | $97.06B | $35.28B | $45.33B |
| Q1 FY2024 | $10.35B-67.6% | $1.33B | $4.21B | $1.66B | $1.25B | $97.09B | $35.61B | $45.52B |
| Q2 FY2024 | $20.89B+101.9% | $2.88B | $8.55B | $3.48B | $3.21B | $98.50B | $35.41B | $47.43B |
| Q3 FY2024 | $31.48B+50.7% | $4.50B | $12.88B | $5.32B | $5.38B | $100.36B | $35.31B | $48.99B |
| Q1 FY2025 | $10.36B-67.1% | $1.51B | $4.24B | $1.72B | $723.0M | $99.04B | $34.19B | $49.39B |
| Q2 FY2025 | $21.22B+104.7% | $3.12B | $8.64B | $3.55B | $2.12B | $101.23B | $35.23B | $50.51B |
| Q3 FY2025 | $32.34B+52.4% | $4.74B | $13.23B | $5.49B | $4.36B | $103.02B | $35.68B | $51.02B |
| Q1 FY2026 | $11.01B-66.0% | $1.65B | $4.43B | $1.86B | $1.19B | $113.28B | $43.16B | $51.93B |
Balance Sheet Summary (Latest Period)
Total Assets
$110.34B
Total Liabilities
$56.94B
Total Equity
$53.41B
Cash & Equivalents
$10.11B
Total Debt
$39.38B
Current Assets
$28.71B
Current Liabilities
$15.19B
Retained Earnings
$59.16B